730 related articles for article (PubMed ID: 30816327)
21. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.
Guo Z; Tu S; Yu S; Wu L; Pan W; Chang N; Zhou X; Song C; Li Y; He Y
Cancer Sci; 2021 Apr; 112(4):1357-1368. PubMed ID: 33416209
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.
Khvorost D; Kendall B; Jazirehi AR
Cells; 2024 Apr; 13(8):. PubMed ID: 38667277
[TBL] [Abstract][Full Text] [Related]
23. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
24. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
25. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
26. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
27. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
28. The Intracellular Domain of CD40 is a Potent Costimulatory Element in Chimeric Antigen Receptors.
Levin-Piaeda O; Levin N; Pozner S; Danieli A; Weinstein-Marom H; Gross G
J Immunother; 2021 Jul-Aug 01; 44(6):209-213. PubMed ID: 34010245
[TBL] [Abstract][Full Text] [Related]
29. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
[TBL] [Abstract][Full Text] [Related]
30. In Vivo Generation of CAR T Cells Selectively in Human CD4
Agarwal S; Hanauer JDS; Frank AM; Riechert V; Thalheimer FB; Buchholz CJ
Mol Ther; 2020 Aug; 28(8):1783-1794. PubMed ID: 32485137
[TBL] [Abstract][Full Text] [Related]
31. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
33. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
34. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
[TBL] [Abstract][Full Text] [Related]
35. Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol.
Yang L; Yin J; Wu J; Qiao L; Zhao EM; Cai F; Ye H
Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34404729
[TBL] [Abstract][Full Text] [Related]
36. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.
Perez A; Al Sagheer T; Nahas GR; Linhares YPL
Front Immunol; 2024; 15():1412002. PubMed ID: 38779668
[TBL] [Abstract][Full Text] [Related]
37. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
38. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
[TBL] [Abstract][Full Text] [Related]
39. Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy.
Bohineust A; Tourret M; Derivry L; Caillat-Zucman S
Bull Cancer; 2021 Oct; 108(10S):S92-S95. PubMed ID: 34920812
[TBL] [Abstract][Full Text] [Related]
40. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]